|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2837-2840.
Prepublished online as a Blood First Edition Paper on June 23, 2005; DOI 10.1182/blood-2005-04-1411.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
Morie A. Gertz,
Martha Q. Lacy,
Angela Dispenzieri,
Philip R. Greipp,
Mark R. Litzow,
Kimberly J. Henderson,
Scott A. Van Wier,
Greg J. Ahmann, and
Rafael Fonseca
From the Division of Hematology, Mayo Clinic, Rochester, MN; and the Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ.
 |
Abstract
|
|---|
Fluorescence in situ hybridization (FISH) is more sensitive than conventional cytogenetics for recognizing chromosomal changes. Several FISH-detected abnormalities have been associated with inferior prognosis, including deletion of chromosomes 17 and 13 ( 13) and t(4;14)(p16.3;q32). We analyzed the prognostic value of FISH testing in 238 patients who received high-dose therapy between January 1990 and September 2001. All patients had pretransplantation cytoplasmic immunoglobulin FISH done on cytospin slides from bone marrow aspirates for t(11;14), t(4;14), and -17(p13.1) (TP53). Time to progression and overall survival were significantly shorter for patients with t(4;14) and those with -17(p13.1) but were not affected by t(11;14). Overall survival was significantly shorter for patients with both t(4;14) and 13 abnormalities than for those with 13 alone (26.8 vs 18.8 months). In a multivariable analysis of the effect of 13 and t(4;14), the risk ratio for t(4;14) was greater than for 13 (2.6 vs 1.5). For high-dose therapy patients, -17(p13) and t(4;14) have clinical importance for estimating time to progression and overall survival. The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches. (Blood. 2005;106:2837-2840)
|
Introduction
|
|---|
Chromosome translocations involving the immunoglobulin heavy chain (IgH) gene locus define distinct entities of multiple myeloma (MM) with clinical, morphologic, immunophenotypic, and therapeutic implications. The 2 most common IgH translocations are t(4;14)(p16.3;q32) and t(11;14)(q13;q32). These translocations result from illegitimate IgH rearrangements.1 The presence of these rearrangements has been correlated with morphology (plasmablastic with t(4;14)(p16.3;q32) and lymphoplasmacytic or small mature with t(11;14)(q13;q32))2 and tumor mass.3 The presence of t(11;14) has also been associated with the presence of CD20 expression on the surface of the cells.4 The t(11;14)(q13;q32) results in up-regulation of cyclin D1 and is the most common translocation detected in myeloma.5 It has been suggested that patients with t(11;14) have better survival6 and response to treatment, particularly high-dose therapy and stem cell support.
In contrast, patients with t(4;14)(p16.3;q32) have an inferior outcome, regardless of the mode of treatment (conventional or high dose).7 The purpose of our study was to evaluate these translocations with fluorescence in situ hybridization (FISH) using patient samples from a single institution where all the patients were treated with high-dose chemotherapy and stem cell transplantation. The study addresses the clinical implications of these chromosome-14 translocations and the -17(p13.1), TP53, deletion on time to progression and overall survival. Multivariable analysis was used to determine whether these abnormalities provide information about patient prognosis not currently available from detection of 13 and the biologic variables  2-microglobulin (B2M) and plasma cell labeling index (PCLI).8
|
Patients and methods
|
|---|
All patients receiving high-dose chemotherapy with stem cell replacement had a pretransplantation bone marrow biopsy performed. All patients gave written informed consent for the collection of additional cells at the time of the bone marrow examination, including separate authorization for genetic studies and separate consent for review of their charts in accord with both U.S. federal regulations and the Health Insurance Portability and Account-ability Act guidelines and the Declaration of Helsinki. The consent form was approved by the institutional review board of Mayo Foundation. In most cases, slides were made with the collected cells, and in some cases, new slides were made from cells frozen in liquid nitrogen. All patients from whom available samples were obtained were included in the analysis. The minimal follow-up for survivors was 36 months. Interphase FISH9 was combined with immunofluorescence for cytoplasmic immunoglobulin FISH to identify exclusively the plasma cell population10 and to ensure that all chromosomal abnormalities detected were part of the plasma cell clone. For the detection of these chromosome abnormalities, we used the commercially available probes LSI IgH/FGFR3 (t(4;14)(p16.3;q32)), LSI IgH/CCND1 XT (t(11;14)(q13;q32)), and LSI p53 (17p13.1 deletion) in combination with CEP17 (Vysis, Downers Grove, IL) under the same conditions previously published by us.11 Trisomies and abnormalities such as c-MAF (16q23), MAFB (20q11), or cyclin D3 (6p21) were not analyzed as part of this study.
Descriptive statistics were used to characterize the patients. The Fisher exact test was used to test for association between translocations and clinical characteristics for continuous variables. The Wilcoxon rank sum test was used to test for differences between patient groups on the basis of their translocation status. The Fisher exact test was used to test differences among levels of categoric variables among patients with FISH abnormalities. Distributions for survival and progression-free survival were estimated with the Kaplan-Meier method. Log-rank testing was used to assess differences in survival for significance. Multivariable analysis was performed by the Cox method.
|
Results
|
|---|
A total of 238 patients were studied between January 1990 and September 2001. Their characteristics are given in Table 1. The outcomes of patients with the various translocations are summarized in Table 2.
t(11;14)(q13;q32)
For the t(11;14)(q13;q32), samples were available to study 197 specimens. This translocation was detected in 34 patients (17%). No differences were found between the patients with and those without the t(11;14)(q13;q32) for age, C-reactive protein level, bone marrow PCLI, serum creatinine, lactate dehydrogenase (LDH), B2M, status at stem cell transplantation, and percentage of bone marrow plasma cells. Overall survival and freedom from progression were not different for patients with t(11;14)(q13;q32). Freedom from progression was 20.1 versus 15.3 months, and overall survival was 36.6 versus 34.8 months (Figure 1). A separate analysis was performed for t(11;14) patients stratified for the presence or absence of 13. No survival advantage was found for t(11;14) in 13-negative patients.
t(4;14)(p16.3;q32)
A successful determination was made in 153 patients. Twenty-six patients (17%) had t(4;14)(p16.3;q32). This chromosome translocation had a profound effect on both time to progression and overall survival. Time to progression for patients with and for those without t(4;14)(p16.3;q32) was 8.2 versus 17.8 months (P = .001), and overall survival was 18.8 versus 43.9 months (P = .001) (Figure 2). Patients with t(4;14)(p16.3;q32) had a higher C-reactive protein, PCLI, and percentage of bone marrow plasma cells (all P = .04). Age, creatinine, LDH, and B2M were not significantly different between the 2 groups. There were no differences in the frequency of t(4;14)(q13;q32) among the patients who underwent transplantation at different phases of their disease. No association was found between t(4;14) and heavy chain type (IgA vs not), light chain type ( vs  ), or the presence of MM bone disease, although only 10% of the patient population had no myeloma bone disease. When the analysis was restricted to the 70 patients who had transplantation upfront in first response, t(4;14)(q13;q32) retained its significance. The median survival rates were 75 months for patients with t(4;14)(p16.3;q32) and 29 months for those without this translocation (P = .01).
View larger version (22K):
[in this window]
[in a new window]
|
Figure 1.. Patients with and without t(11;14)(q13;q32) translocation. (A) Time to progression. (B) Overall survival. BMT indicates bone marrow transplantation.
|
|
TP53
Of 168 patients for whom analysis was possible, -17p13.1 (TP53) was detected in 18 (11%). No differences in TP53 status—positive or negative—were detected for age, creatinine, PCLI, LDH, B2M, bone marrow plasma cells, or status at the time of transplantation. The presence of the TP53 deletions was significant for both the time to progression and overall survival, 8.7 versus 16.1 months and 15.1 versus 38.8 months (P < .01), respectively (Figure 3).
Interaction between abnormalities
To separate the specific effect of t(4;14)(p16.3;q32) from that of 13, an analysis was performed by stratifying 13 among patients with t(4;14)(p16.3;q32). In the larger cohort of 212 patients, FISH detected 13 in 111 (52%). Of these 111 patients positive for 13, 84 had successful studies for t(4;14)(p16.3;q32), of whom 22 (26%) had the abnormality. Survival analysis performed only for patients with 13 showed that the presence of t(4;14)(p16.3;q32) had a significant effect on outcome. When both t(4;14)(p16.3;q32) and 13 were present, overall survival was 18.8 months, significantly worse than for patients who had 13 but not t(4;14)(p16.3;q32) (26.8 months, P = .001). The median progression-free survival times were 12.9 versus 8.2 months, respectively (P = .001), for 13-positive patients without and those with t(4;14). Conversely, in the t(4;14)-positive cohort, the presence or absence of 13 had no effect on survival (19.4 vs 18.8 months).
View larger version (23K):
[in this window]
[in a new window]
|
Figure 2.. Patients with and without t(4;14)(p16.3;q32) translocation. (A) Freedom from progression. (B) Overall survival. BMT indicates bone marrow transplantation.
|
|
View larger version (22K):
[in this window]
[in a new window]
|
Figure 3.. -17p13.1, TP53. (A) Freedom from progression. (B) Overall survival. BMT indicates bone marrow transplantation.
|
|
We constructed a hybrid variable comprising patients who had TP53 deletions, t(4;14)(p16.3;q32), or 13 (n = 120) with those lacking all of the 3 FISH abnormalities (n = 69). Median survival was 26.3 months for those with any of the abnormalities and 51.5 months for those without any abnormality (P = .005).
Assessment of univariate effect of various characteristics
Univariate effect on freedom from progression and overall survival was examined for 203 patients in whom studies were performed for t(4;14)(p16.3;q32), t(11;14)(q13;q32), TP53 deletion, and 13 (Table 3). For freedom from progression, the percentage of plasma cells in bone marrow, PCLI, 13, TP53 deletions, t(4;14)(p16.3; q32), and the status at stem cell transplantation were all significant (P < .05), and for "overall" survival, B2M, percentage of plasma cells in bone marrow, PCLI, 13, TP53 deletions, t(4;14)(p16.3; q32), and status at stem cell transplantation were significant. A Cox proportional hazards model was constructed with the characteristics found to be significant in the univariate analysis (Table 4). In this model, the most important characteristic predicting freedom from progression was whether the patient received the stem cell transplant at the time of relapse (P = .001). In this model, the presence or absence of t(4;14)(p16.3;q32) was significant (P = .001), as was 13 (P = .05). The risk ratio for patients who received a transplant at the time of relapse was 2.3 (compared with transplant in plateau) and 2.6 for the presence of t(4;14)(p16.3; q32). In the survival model, the most important predictors of survival were PCLI and patient status at the time of the stem cell transplantation, with risk ratios of 1.3 and 2.1, respectively. In this model, t(4;14)(p16.3;q32) was significant to .006, with a risk ratio of 2.2. 13 was significant at 0.02, with a risk ratio of 1.7.
When the multivariable analysis was restricted to the 132 patients who had successful analysis for deletion 13, TP53, and t(4;14)(q13;q32) (ie, no missing data), status at transplantation was most significant (P = .001) but t(4;14)(q13;q32) retained its predictive value as well (P = .03), whereas deletion 13 was marginal (P = .08). When the impact of TP53 and t(4;14)(q13;q32) was restricted only to patients who had a transplant more than 12 months after diagnosis (late transplant), both features retained statistical significance in the univariate model, 29.8 versus 16.4 and 29.8 versus 14.2 months for presence or absence of t(4;14) (q13;q32) and TP53, respectively; neither retained significance in the multivariable model.
|
Discussion
|
|---|
The t(11;14)(q13;q32) results in up-regulation of cyclin D1 in MM, as in the case of mantle cell lymphoma.3 In an Eastern Cooperative Oncology Study Group (ECOG) protocol with 336 evaluable patients, 16% had t(11;14)(q13;q32)11 compared with 17% of our high-dose therapy patients, suggesting that the current study had no selection bias. However, in the ECOG study, patients with t(11;14)(q13;q32) appeared to have borderline improvement in survival and response to therapy, whereas our study did not demonstrate any effect on survival or time to progression. Moreau et al6 have suggested that high-dose therapy for patients with t(11;14)(q13;q32) markedly improves survival. Our results do not corroborate this observation.
In our study, deletions of 17p13.1 at the TP53 locus were clinically important (although not independent) for estimating of overall survival and time to progression. Similar observations have been made for patients who received conventional therapy and those who received high-dose therapy. Chang et al12 found that patients with TP53 deletions had significantly shorter progression-free (median 7.9 vs 25.7 months, P = .032) and overall (median 14.7 vs 48.1 months, P = .001) survival than patients without a TP53 deletion. In their study, the abnormality retained its independent value in the multivariable model.
Although FISH detection of 13 was associated with a poor prognosis in our cohort, the presence of t(4;14)(p16.3;q32) was more powerful and provided additional information not provided by the presence of 13 alone. The t(4;14)(p16.3;q32) results in the overexpression of fibroblast growth factor receptor 3 and multiple myeloma SET domain.13-15 The negative prognostic effect of t(4;14)(p16.3;q32) appears to be independent of the actual level of fibroblast growth factor receptor 3 expression.7
In our study, the 2 most important variables were the PCLI of bone marrow (a measure of the fraction of plasma cells in the S phase) and the status of the patient at stem cell transplantation (ie, whether the transplantation was performed at the time of relapse). Because of the low prevalence of these abnormalities (15%), a much larger study is needed to elucidate the actual prognostic implications of these chromosome abnormalities.
Our patients with t(4;14)(p16.3;q32) had a median time to progression of only 8.2 months after stem cell therapy and an overall survival of 18.8 months. This suggests that high-dose therapy, as currently practiced, has minimal benefit for these patients. Whether the addition of nonmyeloablative strategies will overcome these therapeutic limitations is not known; thus, the strategies cannot be deemed the best therapy for this high-risk group of patients. Also, the dismal outcome for t(4;14)(p16.3;q32) after a stem cell transplantation raises the question of the role of allogeneic transplantation in suitable younger candidates. Currently, preclinical and early clinical investigations are being developed for the treatment of patients with IgH chain translocations. Until these therapies are available, patients should be considered candidates for novel therapeutic approaches.
At Mayo Clinic, a FISH panel is routinely performed for all patients with newly diagnosed MM and includes FISH assessment for 4p16.3 (FGFR3), 11q13 (CCND1 XT), 13q14 (Rb1), 13q34 (LAMP1), 14q32 (IGH5', IGH3'), 14q32 (IGH XT), 16q23 (c-MAF), 17p12 (p53), and 17cen (D17Z1). The presence of TP53 deletion, t(4;14), or 13 halves survival from 51.5 to 26.3 months.
|
Footnotes
|
|---|
Submitted April 6, 2005;
accepted June 10, 2005.
Prepublished online as Blood First Edition Paper, June 23, 2005; DOI 10.1182/blood-2005-04-1411.
Supported in part by Hematologic Malignancies Fund of Mayo Clinic. R.F. is a Clinical Investigator of the Damon Runyon Cancer Research Fund. Supported by grants R01 CA83724-01, SPORE P50 CA100707-01, and P01 CA62242 from the National Cancer Institute (NCI) and the Fund to Cure Myeloma, and by NCI grant CA21115-25C.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Correspondence: Morie A. Gertz, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: gertz.morie{at}mayo.edu.
|
References
|
|---|
- Poulsen TS, Silahtaroglu AN, Gisselo CG, Tommerup N, Johnsen HE. Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes. Leukemia. 2002;16: 2148-2155.[CrossRef][Medline]
[Order article via Infotrieve]
- Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia. 2003;17: 2032-2035.[CrossRef][Medline]
[Order article via Infotrieve]
- Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R, Intergroupe Francophone du Myelome. Translocation t(11;14)(q13;q32) is the hall-mark of IgM, IgE, and nonsecretory multiple myeloma variants. Prepublished on October 3, 2002, as DOI 10.1182/blood-2002-08-2436.[Abstract/Free Full Text](Now available as Blood. 2003;101: 1570-1571.)[Abstract/Free Full Text]
- Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Prepublished on April 17, 2003, as DOI 10.1182/blood-2002-11-3333. ([Abstract/Free Full Text]Now available as Blood. 2003;102: 1070-1071.)[Abstract/Free Full Text]
- Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Prepublished on May 1, 2003, as DOI 10.1182/blood-2002-12-3789.[Abstract/Free Full Text](Now available as Blood. 2003;102: 1588-1594.)[Abstract/Free Full Text]
- Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100: 1579-1583.[Abstract/Free Full Text]
- Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Prepublished on October 3, 2002, as DOI 10.1182/blood-2002-06-1675.[Abstract/Free Full Text](Now available as Blood. 2003;101: 1520-1529.)[Abstract/Free Full Text]
- Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81: 3382-3387.[Abstract/Free Full Text]
- Cady FM, Muto DN, Ciabeterri G, Johns A, Gainey Church K, Wolff DJ. Utility of interphase FISH panels for routine clinical cytogenetic evaluation of chronic lymphocytic leukemia and multiple myeloma. J Assoc Genet Technol. 2004;30: 77-81.[Medline]
[Order article via Infotrieve]
- Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100: 1417-1424.[Abstract/Free Full Text]
- Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99: 3735-3741.[Abstract/Free Full Text]
- Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127: 280-284.[CrossRef][Medline]
[Order article via Infotrieve]
- Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol. 2002;118: 514-520.[CrossRef][Medline]
[Order article via Infotrieve]
- Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92: 3025-3034.[Abstract/Free Full Text]
- Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol. 2004;126: 72-76.[CrossRef][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.-L. Harousseau, M. Attal, and H. Avet-Loiseau
The role of complete response in multiple myeloma
Blood,
October 8, 2009;
114(15):
3139 - 3146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, et al.
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Blood,
July 16, 2009;
114(3):
522 - 525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kapoor, S. Kumar, R. Fonseca, M. Q. Lacy, T. E. Witzig, S. R. Hayman, A. Dispenzieri, F. Buadi, P. L. Bergsagel, M. A. Gertz, et al.
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Blood,
July 16, 2009;
114(3):
518 - 521.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A Saad, M. Sharma, and G. M Higa
Treatment of Multiple Myeloma in the Targeted Therapy Era
Ann. Pharmacother.,
February 1, 2009;
43(2):
329 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Yeung and H Chang
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
J. Clin. Pathol.,
July 1, 2008;
61(7):
832 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al.
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
Blood,
May 1, 2008;
111(9):
4700 - 4705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al.
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Blood,
February 1, 2008;
111(3):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart
A Risk-adapted Approach to Myeloma Therapy
ASCO Educational Book,
January 1, 2008;
2008(1):
380 - 384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Blood,
November 1, 2007;
110(9):
3291 - 3300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rosenwald
Genomics in myeloma: the philosopher's stone?
Blood,
April 15, 2007;
109(8):
3126 - 3126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca
Multiple myeloma and FISH (but no CHIPS)
Blood,
April 15, 2007;
109(8):
3132 - 3133.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood,
April 15, 2007;
109(8):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther.,
March 1, 2007;
6(3):
802 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al.
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Mayo Clin. Proc.,
March 1, 2007;
82(3):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca
Strategies for Risk-Adapted Therapy in Myeloma
Hematology,
January 1, 2007;
2007(1):
304 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dingli, G. S. Nowakowski, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, S. V. Rajkumar, P. R. Greipp, M. R. Litzow, D. A. Gastineau, T. E. Witzig, et al.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
Blood,
April 15, 2006;
107(8):
3384 - 3388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Top
Abstract
Introduction